News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Kite Pharma
NEWS
JOBS
IN THE PRESS
NEWS
Deals
5 Tough Questions For Gilead About The Kite Pharma Acquisition
September 12, 2017
·
1 min read
Biotech Bay
Gilead: A Poor Payback Period For Kite Pharma?
September 12, 2017
·
1 min read
Deals
How Gilead and Kite Pharma’s Flirtation Became the Real Thing
September 6, 2017
·
3 min read
Deals
Can Gilead Squeeze $12 Billion From Kite Pharma?
August 30, 2017
·
1 min read
Deals
Gilead And Kite Pharma. A $12 Billion Deal. One More Pricey Drug.
August 29, 2017
·
1 min read
Policy
Kite Pharma Gets A Pass From FDA On Axi-cel Panel Review
August 8, 2017
·
1 min read
Drug Development
Kite Pharma Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy
July 20, 2017
·
3 min read
Policy
Waiting Lists are Already Forming for Novartis AG and Kite Pharma’s Not-Yet Approved CAR-T Drugs
July 7, 2017
·
3 min read
Drug Development
A Look at the Deaths That Plagued Juno and Kite Pharma’s CAR-T Trials
June 27, 2017
·
3 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 8, 2025
·
19 min read
Press Releases
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 8, 2025
·
6 min read
Press Releases
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 8, 2025
·
10 min read
Press Releases
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
November 3, 2025
·
19 min read
Press Releases
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
June 2, 2025
·
17 min read
Press Releases
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
May 15, 2025
·
19 min read
Press Releases
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
December 10, 2024
·
19 min read
Press Releases
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 10, 2024
·
18 min read
Press Releases
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
December 9, 2024
·
19 min read
Biotech Bay
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024
·
9 min read
